Metformin use and improved response to therapy in esophageal adenocarcinoma

Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals

(2011) Ryan P. Merkow et al.   ANNALS OF SURGICAL ONCOLOGY

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

(2011) Meei-Shyuan Lee et al.   BMC CANCER

Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma

(2011) R C Fields et al.   BRITISH JOURNAL OF CANCER

Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells

(2011) Vlad C. Sandulache et al.   CANCER

Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status

(2011) Vlad C. Sandulache et al.   CANCER

Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells

(2011) Ubaldo E. Martinez-Outschoorn et al.   CANCER BIOLOGY & THERAPY

Obesity, metabolic syndrome and esophageal adenocarcinoma: Epidemiology, etiology and new targets

(2011) Aoife M. Ryan et al.   Cancer Epidemiology

Prospective Study of Self-Reported Diabetes and Risk of Upper Gastrointestinal Cancers

(2011) S.-W. Lin et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

(2011) I. Ben Sahra et al.   CANCER RESEARCH

Metformin abolishes increased tumor18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet

(2011) Haider Mashhedi et al.   CELL CYCLE

TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence

(2011) H. D. Skinner et al.   CLINICAL CANCER RESEARCH

Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth

(2011) G. Z. Rocha et al.   CLINICAL CANCER RESEARCH

Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity

(2011) Iris L. Romero et al.   OBSTETRICS AND GYNECOLOGY

Metformin and neoplasia: Implications and indications

(2011) Ahmad Aljada et al.   PHARMACOLOGY & THERAPEUTICS

Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma

(2010) Kotaro Hirashima et al.   ANNALS OF SURGICAL ONCOLOGY

Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

(2010) Kenneth L. Meredith et al.   ANNALS OF SURGICAL ONCOLOGY

The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

(2010) Issam Ben Sahra et al.   Autophagy

Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drug

(2010) Tamer Özülker et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells

(2010) Toran Sanli et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

(2009) Sao Jiralerspong et al.   JOURNAL OF CLINICAL ONCOLOGY